InflaRx (IFRX) Shares Outstanding (2017 - 2026)
InflaRx (IFRX) posted Shares Outstanding (Entity) of $1.7 billion for Q4 2025, down 0.68% sequentially from $1.7 billion in Q2 2025, and up 14.2% YoY from $1.5 billion in Q4 2024.
InflaRx (IFRX) Shares Outstanding (2017 - 2026) Analysis & Trends
InflaRx has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $1.7 billion in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 14.2% year-over-year to $1.7 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 billion (up 14.2% YoY) and the FY2025 annual result came in at $1.7 billion, up 14.2% from the prior year.
- Shares Outstanding (Entity) declined to $1.7 billion in Q4 2025 per IFRX's latest filing, from $1.7 billion in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $1.7 billion in Q2 2025 and troughed at $1.0 billion in Q4 2021.
- A 5-year average of $1.4 billion and a median of $1.4 billion in 2023 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) declined 24.97% in 2022, then climbed 28.92% in 2023.
- Over 5 years, Shares Outstanding (Entity) stood at $1.0 billion in 2021, then increased by 6.19% to $1.1 billion in 2022, then gained by 24.28% to $1.4 billion in 2023, then increased by 7.24% to $1.5 billion in 2024, then advanced by 14.2% to $1.7 billion in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $1.7 billion, $1.7 billion, and $1.5 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 67.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.29 Mn |
| Dec 31, 2025 | 67.29 Mn |
| Sep 30, 2025 | 67.75 Mn |
| Jun 30, 2025 | 67.75 Mn |
| Mar 31, 2025 | 58.92 Mn |
| Dec 31, 2024 | 58.92 Mn |
| Sep 30, 2024 | 58.88 Mn |
| Jun 30, 2024 | 58.88 Mn |
| Mar 31, 2024 | 54.94 Mn |
| Dec 31, 2023 | 54.94 Mn |
| Sep 30, 2023 | 56.99 Mn |
| Jun 30, 2023 | 56.99 Mn |
| Mar 31, 2023 | 44.21 Mn |
| Dec 31, 2022 | 44.21 Mn |
| Sep 30, 2022 | 44.20 Mn |
| Jun 30, 2022 | 44.20 Mn |
| Mar 31, 2022 | 41.63 Mn |
| Dec 31, 2021 | 41.63 Mn |
| Sep 30, 2021 | 44.19 Mn |
| Jun 30, 2021 | 44.19 Mn |